On Wednesday, Enveric Biosciences Inc. (NASDAQ:ENVB), a biotechnology firm developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological conditions, released results from a quantitative electroencephalography study assessing its lead compound, EB-003. Conducted in mice, the trial verified central nervous system penetration by showing altered electrical oscillations in cortical regions without causing the severe physical reactions or seizure-like events triggered by traditional psychedelics.

